Previous close | 1.3500 |
Open | N/A |
Bid | 0.8000 |
Ask | 1.3000 |
Strike | 4.00 |
Expiry date | 2024-05-17 |
Day's range | 1.3500 - 1.3500 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
A week ago, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) came out with a strong set of quarterly numbers that could...
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript May 7, 2024 Heron Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.0209, expectations were $-0.08. HRTX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. My […]